{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:07:46Z","timestamp":1792202866770,"version":"4.4.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T00:00:00Z","timestamp":1482278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.clinthera.2016.12.011","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T22:32:59Z","timestamp":1484173979000},"page":"430-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review"],"prefix":"10.1016","volume":"39","author":[{"given":"Robert T.","family":"Keenan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.12.011_bib1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.12.011_bib2","series-title":"Kelley\u2019s Textbook of Rheumatology","article-title":"Etiology and pathogenesis of hyperuricemia and gout","author":"Keenan","year":"2013"},{"issue":"suppl 10","key":"10.1016\/j.clinthera.2016.12.011_bib3","first-page":"S888","article-title":"Annual medical care expenditures among US adults with gout, 2005\u20132011","volume":"66","author":"Cisternas","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.12.011_bib4","first-page":"498","article-title":"Gout in ambulatory care settings in the United States","volume":"35","author":"Krishnan","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2016.12.011_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3111\/13696998.2010.540874","article-title":"Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy","volume":"14","author":"Edwards","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2016.12.011_bib6","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","article-title":"Health-related quality of life in gout: a systematic review","volume":"52","author":"Chandratre","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2016.12.011_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","article-title":"Update on gout: new therapeutic strategies and options","volume":"6","author":"Terkeltaub","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2016.12.011_bib8","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/rheumatology\/kep087","article-title":"Treating to target: a strategy to cure gout","volume":"48","author":"Perez-Ruiz","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2016.12.011_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2016.12.011_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3199","article-title":"Epidemiology of gout","volume":"12","author":"Roddy","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2016.12.011_bib11","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar3483","article-title":"Bone destruction by receptor activator of nuclear factor kappaB ligand-expressing T cells in chronic gouty arthritis","volume":"13","author":"Lee","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2016.12.011_bib12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/art.1780180722","article-title":"Pathology of the synovial membrane in gout. Light and electron microscopic studies. Interpretation of crystals in electron micrographs","volume":"18","author":"Schumacher","year":"1975","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.12.011_bib13","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/rheumatology\/kep278","article-title":"An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs","volume":"48","author":"Carter","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2016.12.011_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1759720X14542960","article-title":"Imaging in gout: A review of the recent developments","volume":"6","author":"Chowalloor","year":"2014","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.clinthera.2016.12.011_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12325-014-0175-z","article-title":"A review of uric acid, crystal deposition disease, and gout","volume":"32","author":"Perez-Ruiz","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2016.12.011_bib16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice. Gout","volume":"364","author":"Neogi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.12.011_bib17","first-page":"499","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005"},{"key":"10.1016\/j.clinthera.2016.12.011_bib18","series-title":"Goldman\u2019s Cecil Medicine","first-page":"1737","article-title":"Crystal deposition diseases","author":"Edwards","year":"2012"},{"key":"10.1016\/j.clinthera.2016.12.011_bib19","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2016.12.011_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ard.42.Suppl_1.12","article-title":"Studies of urate crystallisation in relation to gout","volume":"42","author":"Fiddis","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.12.011_bib21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.12.011_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/ard.2006.062091","article-title":"EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"66","author":"Zhang","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.12.011_bib23","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clinthera.2016.12.011_bib24","first-page":"783","article-title":"Updated EULAR evidence-based recommendations for the management of gout [Abstract SAT0531]","volume":"73","author":"Richette","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.12.011_bib25","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2016.12.011_bib26","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.12.011_bib27","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clinthera.2016.12.011_bib28","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1136\/annrheumdis-2012-201838","article-title":"Purine-rich foods: an innocent bystander of gout attacks?","volume":"71","author":"Richette","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.12.011_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acr.22059","article-title":"Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy","volume":"66","author":"Dalbeth","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clinthera.2016.12.011_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.semarthrit.2014.01.004","article-title":"Up-titration of allopurinol in patients with gout","volume":"44","author":"Jennings","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.12.011_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/00325481.2016.1113840","article-title":"A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift","volume":"128","author":"Khanna","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2016.12.011_bib32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: The LASSO study","volume":"45","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.12.011_bib33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/BOR.0000000000000141","article-title":"Overcoming adherence issues and other barriers to optimal care in gout","volume":"27","author":"Nasser-Ghodsi","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clinthera.2016.12.011_bib34","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims","volume":"31","author":"Riedel","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2016.12.011_bib35","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/ar2659","article-title":"Adherence with urate-lowering therapies for the treatment of gout","volume":"11","author":"Harrold","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2016.12.011_bib36","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","article-title":"Medication adherence in gout: a systematic review","volume":"66","author":"De Vera","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clinthera.2016.12.011_bib37","year":"2003","journal-title":"Adherence to Long-Term Therapy"},{"key":"10.1016\/j.clinthera.2016.12.011_bib38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2474-13-180","article-title":"Patients\u2019 knowledge and beliefs concerning gout and its treatment: a population based study","volume":"13","author":"Harrold","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clinthera.2016.12.011_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1742395310378761","article-title":"Patients and providers view gout differently: a qualitative study","volume":"6","author":"Harrold","year":"2010","journal-title":"Chronic Illn"},{"key":"10.1016\/j.clinthera.2016.12.011_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3810\/pgm.2014.05.2774","article-title":"Physician adherence to ACR gout treatment guidelines: perception versus practice","volume":"126","author":"Oderda","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2016.12.011_bib41","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/rheumatology\/ket158","article-title":"Primary care providers\u2019 knowledge, beliefs and treatment practices for gout: results of a physician questionnaire","volume":"52","author":"Harrold","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2016.12.011_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/BOR.0b013e328335eee3","article-title":"A roadmap for education to improve the quality of care in gout","volume":"22","author":"Ogdie","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clinthera.2016.12.011_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2016.12.011_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.18773\/austprescr.2016.047","article-title":"The management of gout","volume":"39","author":"Finch","year":"2016","journal-title":"Aust Prescrib"},{"key":"10.1016\/j.clinthera.2016.12.011_bib45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/14656566.2015.997213","article-title":"Advances in pharmacotherapy for the treatment of gout","volume":"16","author":"Robinson","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2016.12.011_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.12.011_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2016.12.011_bib48","first-page":"68","article-title":"No increased risk of chronic kidney disease with allopurinol use [abstract]","author":"Vargas-Santos","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2016.12.011_bib49","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.12.011_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1759720X16646703","article-title":"Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications","volume":"8","author":"Sattui","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.clinthera.2016.12.011_bib51","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jdiacomp.2014.11.013","article-title":"Glycemic variability and diabetes retinopathy: a missing link","volume":"29","author":"Hsu","year":"2015","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.clinthera.2016.12.011_bib52","unstructured":"Takeda Pharmaceuticals. Uloric (febuxostat) [prescribing information]. http:\/\/general.takedapharm.com\/content\/file.aspx?filetypecode=ULORICPI&cacheRandomizer=074f14da-9978-40fe-a98a-86a4aa30be8f. Accessed December 7, 2016."},{"key":"10.1016\/j.clinthera.2016.12.011_bib53","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.rdc.2012.08.008","article-title":"Safety of urate-lowering therapies: managing the risks to gain the benefits","volume":"38","author":"Keenan","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.clinthera.2016.12.011_bib54","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.12.011_bib55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","article-title":"Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy","volume":"20","author":"Baraf","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2016.12.011_bib56","unstructured":"Krystexxa (pegloticase) [prescribing information]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125293s034lbl.pdf. Accessed November 21, 2016."},{"key":"10.1016\/j.clinthera.2016.12.011_bib57","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/rheumatology\/keu043","article-title":"Treat to target in gout by combining two modes of action","volume":"53","author":"Jansen","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2016.12.011_bib58","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/BOR.0000000000000146","article-title":"New medications in development for the treatment of hyperuricemia of gout","volume":"27","author":"Diaz-Torne","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clinthera.2016.12.011_bib59","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.2147\/DDDT.S85193","article-title":"Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males","volume":"9","author":"Shen","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2016.12.011_bib60","doi-asserted-by":"crossref","unstructured":"Bardin T, Keenan RT, Khanna PP, et al. Ann Rheum Dis. Published Online First [November 7, 2016]. http:\/\/dx.doi.org\/10.1136\/annrheumdis-2016-209213.","DOI":"10.1136\/annrheumdis-2016-209213"},{"key":"10.1016\/j.clinthera.2016.12.011_bib61","unstructured":"Zurampic (lesinurad) [prescribing information]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207988lbl.pdf. Accessed November 18, 2016."},{"key":"10.1016\/j.clinthera.2016.12.011_bib62","unstructured":"Adherence to Long-Term Therapy. 2003. http:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_full_report.pdf. Accessed November 8, 2015."},{"key":"10.1016\/j.clinthera.2016.12.011_bib63","unstructured":"JW Pharmaceutical. URC102 Studies. https:\/\/clinicaltrials.gov\/ct2\/results\/displayOpt?flds=a&flds=b&flds=i&flds=f&flds=c&submit_fld_opt=on&term=URC102&show_flds=Y. Accessed March 24, 2016."},{"key":"10.1016\/j.clinthera.2016.12.011_bib64","unstructured":"Chugai Pharmaceutical. Development Pipeline. Available from: http:\/\/www.chugai-pharm.co.jp\/english\/ir\/pdf\/130725ePipeline.pdf. Accessed March 24, 2016."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816309249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816309249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:23:55Z","timestamp":1536107035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816309249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0149291816309249"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}